Trial Profile

DAREON-7: A Phase I, Open-label, Dose Escalation and Expansion Trial to Investigate Safety and Tolerability of BI 764532 Intravenous Infusions in Combination With Standard of Care (Platinum and Etoposide) in First-line Treatment of Patients With Neuroendocrine Carcinomas (NEC)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 27 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Etoposide (Primary) ; Obrixtamig (Primary)
Indications Neuroendocrine carcinoma
Focus Adverse reactions
Acronyms DAREON™-7
Sponsors Boehringer Ingelheim

22 May 2025 According to a Boehringer Ingelheim media release, company will present the latest data from this trial at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
30 Oct 2024 Planned End Date changed from 1 Dec 2025 to 10 Aug 2026.
30 Oct 2024 Planned primary completion date changed from 5 Nov 2025 to 6 Jul 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com